Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptahem ABXSAT:APTA +21.41%29 3-Year Share Buyback Ratio is -110.40 as of Jun. 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,184 Biotechnology companies, Aptahem AB ranks worse than 91.89% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Aptahem AB's current 3-Year Share Buyback Ratio was -110.40%.
The historical rank and industry rank for Aptahem AB's 3-Year Share Buyback Ratio or its related term are showing as below:
XSAT:APTA'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -110.4 Med: -52 Max: -40.3
Current: -110.4
During the past 12 years, Aptahem AB's highest 3-Year Share Buyback Ratio was -40.30%. The lowest was -110.40%. And the median was -52.00%.
XSAT:APTA's 3-Year Share Buyback Ratio is ranked worse than 91.89% of 1184
companies
in the Biotechnology industry
Industry Median: -11.6
vs XSAT:APTA: -110.40
Aptahem AB (XSAT:APTA) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Aptahem AB 3-Year Share Buyback Ratio Related Terms
XSAT:APTA vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Aptahem AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptahem AB 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptahem AB's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Aptahem AB's 3-Year Share Buyback Ratio falls into.
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -110.40 mean?
Aptahem AB (XSAT:APTA) has a 3-Year Share Buyback Ratio of -110.40 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Aptahem AB and its competitors. According to the industry distribution chart, Aptahem AB ranks #1088 out of 1184 companies in the Biotechnology industry, placing it in the top 91.9%.
Is Aptahem AB's 3-Year Share Buyback Ratio too high?
Aptahem AB's current 3-Year Share Buyback Ratio is -110.40. Based on the distribution chart, Aptahem AB ranks #1088 out of 1184 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptahem AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptahem AB ranks #1088 out of 1184 companies for 3-Year Share Buyback Ratio. This places Aptahem AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Aptahem AB and its competitors. Aptahem AB's current 3-Year Share Buyback Ratio is -110.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current 3-Year Share Buyback Ratio of -110.40. The current 3-Year Share Buyback Ratio is -110.40. Aptahem AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current 3-Year Share Buyback Ratio is -110.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
29GF Score
Get the complete analysis for XSAT:APTA
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:APTA has been successfully added to your 
